NEW YORK – NeoGenomics announced on Monday that it has entered a strategic partnership with the Biomarker Collaborative to help cancer patients with certain biomarkers find resources.
The Biomarker Collaborative is a community of biomarker groups with a focus on helping patients navigate the healthcare system and ensuring they receive comprehensive biomarker testing. It also advocates to increase screening and support access to clinical trials.
Under the agreement, when a patient's lung cancer biomarker is identified with NeoGenomics' tests, the results will include a resource page with education about the biomarker and connections to support groups. The resource page "is a discussion starting point helping empower patients to better understand their diagnosis with the support of peers walking a similar journey," NeoGenomics said in a statement.
"Both the patient and the patient's oncologist will now see in the actual report ordered by the oncologist and issued by NeoGenomics that there is a biomarker group directly relevant to the patient's diagnosis," John Hallick, co-president of the Biomarker Collaborative, said in a statement.